137 related articles for article (PubMed ID: 36272959)
21. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma.
Bersanelli M; Rebuzzi SE; Roviello G; Catalano M; Brunelli M; Rizzo M
Hum Vaccin Immunother; 2023 Dec; 19(1):2171672. PubMed ID: 36758960
[TBL] [Abstract][Full Text] [Related]
22. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
[TBL] [Abstract][Full Text] [Related]
23. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
Voss MH; Molina AM; Chen YB; Woo KM; Chaim JL; Coskey DT; Redzematovic A; Wang P; Lee W; Selcuklu SD; Lee CH; Berger MF; Tickoo SK; Reuter VE; Patil S; Hsieh JJ; Motzer RJ; Feldman DR
J Clin Oncol; 2016 Nov; 34(32):3846-3853. PubMed ID: 27601542
[TBL] [Abstract][Full Text] [Related]
24. Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.
Maughan BL
Curr Oncol Rep; 2022 Sep; 24(9):1201-1208. PubMed ID: 35438388
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.
Yildiz I; Ekenel M; Akman T; Kocar M; Uysal M; Kanitez M; Varol U; Bayoglu IV; Tural D; Kaplan MA; Avci N; Sürmeli Z; Dede İ; Ulaş A; Yazici O; Basaran M
Anticancer Res; 2014 Aug; 34(8):4329-34. PubMed ID: 25075067
[TBL] [Abstract][Full Text] [Related]
27. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
Escudier B; Molinie V; Bracarda S; Maroto P; Szczylik C; Nathan P; Negrier S; Weiss C; Porta C; Grünwald V; Albiges L
Eur J Cancer; 2016 Dec; 69():226-235. PubMed ID: 27680407
[TBL] [Abstract][Full Text] [Related]
28. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
29. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
[TBL] [Abstract][Full Text] [Related]
30. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
31. Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Massari F; Mollica V; Fiala O; De Giorgi U; Kucharz J; Vitale MG; Molina-Cerrillo J; Facchini G; Seront E; Lenci E; Bourlon MT; Carrozza F; Pichler R; Lolli C; Myint ZW; Kanesvaran R; Torniai M; Rescigno P; Gomez de Liaño A; Zakopoulou R; Buti S; Porta C; Grande E; Santoni M
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38575409
[TBL] [Abstract][Full Text] [Related]
32. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
[TBL] [Abstract][Full Text] [Related]
33. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 May; 94(2):238-50. PubMed ID: 25638704
[TBL] [Abstract][Full Text] [Related]
35. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
Staehler M; Goebell PJ; Müller L; Emde TO; Wetzel N; Kruggel L; Jänicke M; Marschner N;
Int J Cancer; 2020 Mar; 146(5):1307-1315. PubMed ID: 31498894
[TBL] [Abstract][Full Text] [Related]
36. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
[TBL] [Abstract][Full Text] [Related]
37. Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma.
An J; Packiam VT; Chennamadhavuni A; Richards J; Jain J; Mott SL; Garje R
Front Oncol; 2021; 11():786307. PubMed ID: 35083144
[TBL] [Abstract][Full Text] [Related]
38. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
39. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
Kroeger N; Xie W; Lee JL; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Srinivas S; Vaishamayan UN; Rha SY; Pal SK; Yuasa T; Donskov F; Agarwal N; Kollmannsberger CK; Tan MH; North SA; Rini BI; Choueiri TK; Heng DY
Cancer; 2013 Aug; 119(16):2999-3006. PubMed ID: 23696129
[TBL] [Abstract][Full Text] [Related]
40. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
